Related Experiment Videos
Generation of active immunotoxins containing recombinant restrictocin
1Immunochemistry Laboratory, National Institute of Immunology, New Delhi, India.
Summary
Restrictocin, a fungal toxin, effectively inhibits protein synthesis. Engineered as an immunotoxin targeting cancer cells, it shows promise for targeted cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Restrictocin, a toxin from *Aspergillus restrictus*, inhibits eukaryotic protein synthesis.
- Recombinant restrictocin can be produced in large quantities using *Escherichia coli*.
Purpose of the Study:
- To evaluate the potential of restrictocin as a component of targeted cancer therapy.
- To construct and assess immunotoxins using recombinant restrictocin.
Main Methods:
- Production and purification of recombinant restrictocin in *E. coli*.
- Construction of two immunotoxins by linking restrictocin to an anti-transferrin receptor antibody via cleavable and stable linkages.
- Assessment of immunotoxin activity on receptor-bearing cells in tissue culture and in vivo toxicity in mice.
Main Results:
- Recombinant restrictocin exhibited low toxicity and poor immunogenicity in mice.
- Both immunotoxins demonstrated specific cytotoxic activity against transferrin receptor-bearing cells.
- The immunotoxin with a cleavable linkage showed greater activity than the one with a stable linkage.
Conclusions:
- Recombinant restrictocin is a viable and safe component for developing targeted immunotoxins.
- Immunotoxins derived from restrictocin hold significant potential for targeted cancer therapy.
- Cleavable linkages enhance the efficacy of restrictocin-based immunotoxins.